Table 2 Demographics and clinical characteristics at index visit for first-line ETN, ADA, and JAKi monotherapy initiators with 6 months of follow-up

Age, years, mean (SD)

52.4 (13.2)

54.3 (11.1)

62.5 (12.0)

Women, n (%)

155 (78.7)

140 (73.3)

90 (76.9)

White, n/N (%)

160/196 (81.6)

156/189 (82.5)

102/117 (87.2)

BMI, kg/m², mean (SD)

30.2 (7.7)

31.1 (7.1)

30.5 (6.6)

Duration of RA, years, mean (SD)

5.7 (7.3)

5.3 (6.3)

7.3 (8.9)

Rheumatoid factor positive, n/N (%)

83/118 (70.3)

72/118 (61.0)

34/64 (53.1)

CCP positive, n/N (%)

80/119 (67.2)

73/117 (62.4)

42/70 (60.0)

College education or above, n (%)

115 (60.2)

100 (55.6)

56 (49.6)

History of comorbidities, n (%)

 Cardiovascular disease

16 (8.1)

25 (13.1)

12 (10.3)

 Malignancy

4 (2.0)

11 (5.8)

13 (11.1)

 Serious infections

6 (3.0)

15 (7.9)

5 (4.3)

 Fractures

49 (24.9)

57 (29.8)

36 (30.8)

 Deep vein thrombosis/pulmonary embolism

1 (0.5)

2 (1.0)

2 (1.7)

Medication history

 Prior number of csDMARDs received (including current csDMARD), mean (SD)

1.2 (0.9)

1.6 (1.1)

1.4 (1.0)

 History of prednisone use, n (%)

94 (47.7)

99 (51.8)

54 (46.2)

Prednisone use, n (%)

51 (25.9)

48 (25.1)

27 (23.1)

 Dose of prednisone, mg, mean (SD)

8.3 (5.2)

8.9 (9.0)

7.9 (5.1)

Disease activity and PROs, mean (SD)

 TJC-28

6.1 (6.2)

5.5 (5.8)

7.2 (8.1)

 SJC-28

4.6 (5.1)

3.5 (4.4)

5.5 (5.6)

 PhGA^a

37.1 (23.8)

31.3 (23.5)

31.6 (23.7)

 PtGA^a

46.6 (26.2)

46.7 (26.5)

41.9 (28.9)

 CDAI

19.2 (12.7)

16.8 (11.6)

20.0 (15.7)

 Patient pain^a

49.4 (28.4)

52.5 (29.7)

42.8 (30.7)

 Patient fatigue^a

45.7 (31.1)

51.4 (30.3)

44.2 (31.4)

 mHAQ

0.5 (0.5)

0.6 (0.5)

0.5 (0.5)

 EQ-5D

0.7 (0.2)

0.7 (0.2)

0.7 (0.2)

 Patients with morning stiffness, n (%)

162 (89.5)

150 (85.2)

89 (84.8)

 Duration of morning stiffness, hours, mean (SD)

2.4 (4.2)

2.2 (3.7)

2.2 (4.3)